- Inhibits IL-1β expression while enhancing release of protolerogenic components of the inflammasome, such as indoleamine 2,3-dioxygenase (IDO) and IL-33 - Promotes differentiation of tolerogenic CD103+ DCs and reduces differentiation/expansion of Th1 and Th17 cells in the intestinal mucosa and at the sites of autoimmunity within the pancreatic lymph nodes (PLN) - Reduces the Teff/Treg cell balance in the gut mucosa and PLN. Here, IL33 is linked to Autoimmunity.